CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Portland, Oregon, United States and 173 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Portland, Oregon, United States and 47 other locations
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...
Phase 1
Portland, Oregon, United States and 8 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Portland, Oregon, United States and 23 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Portland, Oregon, United States and 13 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Portland, Oregon, United States and 110 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Portland, Oregon, United States and 85 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes l...
Phase 1, Phase 2
Portland, Oregon, United States and 18 other locations
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL...
Phase 1, Phase 2
Portland, Oregon, United States and 9 other locations
chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor recept...
Phase 1
Portland, Oregon, United States
Clinical trials
Research sites
Resources
Legal